ATE260666T1 - Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren - Google Patents
Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumorenInfo
- Publication number
- ATE260666T1 ATE260666T1 AT95906825T AT95906825T ATE260666T1 AT E260666 T1 ATE260666 T1 AT E260666T1 AT 95906825 T AT95906825 T AT 95906825T AT 95906825 T AT95906825 T AT 95906825T AT E260666 T1 ATE260666 T1 AT E260666T1
- Authority
- AT
- Austria
- Prior art keywords
- cellular vaccine
- treatment
- solid tumors
- tumor
- malignant solid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 229940030156 cell vaccine Drugs 0.000 title abstract 3
- 230000003211 malignant effect Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001678 irradiating effect Effects 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/100,691 US5820872A (en) | 1992-11-18 | 1993-07-30 | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor |
PCT/US1994/008301 WO1995003814A1 (en) | 1993-07-30 | 1994-07-25 | Cellular vaccine and methods of use for the treatment of solid tumor malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE260666T1 true ATE260666T1 (de) | 2004-03-15 |
Family
ID=22281052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95906825T ATE260666T1 (de) | 1993-07-30 | 1994-07-25 | Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren |
Country Status (7)
Country | Link |
---|---|
US (1) | US5820872A (de) |
EP (1) | EP0719150B1 (de) |
JP (1) | JPH09500652A (de) |
AT (1) | ATE260666T1 (de) |
DE (1) | DE69433590T2 (de) |
ES (1) | ES2213158T3 (de) |
WO (1) | WO1995003814A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5651993A (en) * | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
US5462733A (en) * | 1993-02-04 | 1995-10-31 | Yale University | Immune system modulation using psoralens activated with visible light |
US8021667B2 (en) * | 1994-11-16 | 2011-09-20 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Compositions for immunotherapy and uses thereof |
US5882328A (en) * | 1995-01-13 | 1999-03-16 | Qlt Phototherapeutics, Inc. | Method to prevent transplant rejection |
JP3702330B2 (ja) * | 1995-01-13 | 2005-10-05 | キュー エル ティー インク. | 移植の拒絶を防止する方法 |
US6207147B1 (en) * | 1996-10-11 | 2001-03-27 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
CA2249412A1 (en) * | 1996-03-22 | 1997-09-25 | Yale University | Methods for inducing immune responsiveness in a subject |
CN1121217C (zh) * | 1996-03-29 | 2003-09-17 | 特拉科斯有限公司 | 免疫原性组合物 |
US6228995B1 (en) | 1996-04-09 | 2001-05-08 | Therakos, Inc. | Method for removal of psoralens from biological fluids |
DE19635086C1 (de) * | 1996-08-30 | 1998-02-26 | Rheinische Braunkohlenw Ag | Verfahren zum Betrieb eines mit Braunkohle befeuerten Kraftwerkes sowie ein derartiges Kraftwerk |
US6465251B1 (en) * | 1996-11-13 | 2002-10-15 | Dana-Farber Cancer Institute, Inc. | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin |
JP4198221B2 (ja) * | 1997-06-13 | 2008-12-17 | 株式会社半導体エネルギー研究所 | 光学活性化合物、反強誘電性液晶組成物、反強誘電性液晶組成物のしきい値を低減する方法及び光学活性化合物の製造方法 |
CN1230212C (zh) * | 1997-07-10 | 2005-12-07 | 特拉科斯有限公司 | 肠和膀胱炎症紊乱的治疗 |
CA2304952C (en) * | 1997-09-29 | 2012-01-03 | The Austin Research Institute | Mannose-receptor bearing cells and antigen conjugate for immunotherapy |
GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
US7109031B2 (en) * | 1999-04-20 | 2006-09-19 | Yale University | Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
US20050084966A1 (en) * | 1999-04-20 | 2005-04-21 | Edelson Richard L. | Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
US20080241815A1 (en) * | 1999-04-20 | 2008-10-02 | Edelson Richard L | Methods for Inducing the Differentiation of Blood Monocytes into Functional Dendritic Cells |
EP1176986B1 (de) * | 1999-04-20 | 2018-07-04 | Yale University | Differenzierung von monozyten in funktionale dentritische zellen |
US20050158856A1 (en) * | 1999-04-20 | 2005-07-21 | Edelson Richard L. | Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials |
US6219584B1 (en) * | 1999-07-09 | 2001-04-17 | Therakos, Inc. | Method and system for determining an effective amount of light energy to delivery to fluids having targets for the light energy |
US6495366B1 (en) | 1999-09-03 | 2002-12-17 | Therakos, Inc. | Uninterrupted flow pump apparatus and method |
US6494865B1 (en) * | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US7872050B2 (en) * | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
US8501818B2 (en) * | 2005-03-14 | 2013-08-06 | Ceptaris Therapeutics, Inc. | Stabilized compositions of alkylating agents and methods of using same |
US20110039943A1 (en) * | 2005-03-14 | 2011-02-17 | Robert Alonso | Methods for treating skin disorders with topical nitrogen mustard compositions |
PL3494960T3 (pl) | 2008-03-27 | 2021-05-17 | Helsinn Healthcare Sa | Stabilizowane kompozycje środków alkilujących i sposoby ich zastosowania |
US20120052544A1 (en) * | 2010-08-24 | 2012-03-01 | Mcgarry Thomas J | Enucleation of cells with psoralens |
JP6966478B2 (ja) * | 2016-02-02 | 2021-11-17 | イミュノライト・エルエルシー | フォスファー含有薬剤活性化剤、その懸濁液、懸濁液を含むシステム、及び使用方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670386A (en) * | 1980-05-23 | 1987-06-02 | Stephen Sugaar | Cancer tests using tumor antigen generated lymphokines and compositions |
US4753884A (en) * | 1986-01-28 | 1988-06-28 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
US4838852A (en) * | 1987-03-27 | 1989-06-13 | Therakos, Inc. | Active specific immune suppression |
US4895717A (en) * | 1987-07-10 | 1990-01-23 | The United States Of America As Represented By The Secretary Of Agriculture | Revertant serotype 1 Marek's disease vaccine |
US5147289A (en) * | 1990-03-29 | 1992-09-15 | Therakos, Inc | Non-specific immune system enhancement |
US5651993A (en) * | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
US5462733A (en) * | 1993-02-04 | 1995-10-31 | Yale University | Immune system modulation using psoralens activated with visible light |
-
1993
- 1993-07-30 US US08/100,691 patent/US5820872A/en not_active Expired - Lifetime
-
1994
- 1994-07-25 DE DE69433590T patent/DE69433590T2/de not_active Expired - Lifetime
- 1994-07-25 ES ES95906825T patent/ES2213158T3/es not_active Expired - Lifetime
- 1994-07-25 EP EP95906825A patent/EP0719150B1/de not_active Expired - Lifetime
- 1994-07-25 WO PCT/US1994/008301 patent/WO1995003814A1/en active IP Right Grant
- 1994-07-25 AT AT95906825T patent/ATE260666T1/de active
- 1994-07-25 JP JP7505901A patent/JPH09500652A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2213158T3 (es) | 2004-08-16 |
DE69433590T2 (de) | 2004-08-05 |
DE69433590D1 (de) | 2004-04-08 |
EP0719150A1 (de) | 1996-07-03 |
US5820872A (en) | 1998-10-13 |
EP0719150A4 (de) | 1998-07-29 |
JPH09500652A (ja) | 1997-01-21 |
EP0719150B1 (de) | 2004-03-03 |
WO1995003814A1 (en) | 1995-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE260666T1 (de) | Zellulärer impfstoff und deren verwendung für die behandlung von malignen, soliden tumoren | |
US5635188A (en) | Anti-cancer vaccine | |
DE3806565C2 (de) | ||
Korbelik et al. | Photodynamic therapy-generated vaccines: relevance of tumour cell death expression | |
Jurin et al. | Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel | |
ATE246513T1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
BR9607894A (pt) | Processo para tratar tumores | |
DE3789082D1 (de) | Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors. | |
US6338853B1 (en) | Anti-cancer vaccine | |
PT910407E (pt) | Metodo e composicao para modificar a conformacao de antigenios multi-epitopicos de modo a iniciar uma resposta imunitaria | |
US5194384A (en) | Method for preparing human meloma vaccine | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
RU93042874A (ru) | Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии | |
HUT64569A (en) | A process for preparing polypeptide-type compounds usefules for medical treatment of the human body | |
Szmigielski et al. | Local microwave hyperthermia (43° C) and stimulation of the macrophage and T-lymphocyte systems in treatment of Guerin epithelioma in rats | |
Hadar et al. | Lymphocyte-induced angiogenesis factor is produced by L3T4+ murine T lymphocytes, and its production declines with age | |
Holmes et al. | Immunotherapy of malignancy in humans: Current status | |
ATE198711T1 (de) | Gammaglobuline enthaltende immunotherapeutische präparate für die behandlung von krebskrankheiten | |
Suit et al. | Radiation therapy and Corynebacterium parvum in the treatment of murine tumors | |
US5993829A (en) | Anti-cancer vaccine | |
Milas et al. | Combination of C. parvum and specific immunization against artificial pulmonary metastases in mice | |
Milas et al. | Concomitant immunity to pulmonary metastases of a murine fibrosarcoma: influence of removal of primary tumor by radiation or surgery, of active specific immunization and treatment with Corynebacterium granulosum | |
Leith | Increase in Hypoxic Fraction of Human Colon Tumor Xenografts by Preirradiation of Tumor Bed¹ | |
Hahn et al. | The significance of fractionation regimens in radiation and combined hyperthermia using a murine fibrosarcoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0719150 Country of ref document: EP |